In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...

The FDA’s abrupt shift on UniQure’s treatment reflects an agency that, under current leadership, is as unpredictable as its been in years, some analysts said.

Last month, “historic positive results” from uniQure’s gene therapy snapped the Huntington’s community out of years of failure. As the biotech prepares to submit for FDA approval, BioSpace looks at ...

Huntington’s disease (HD) is a condition that is hereditary and causes ... According to the National Health Service, early signs may include trouble focusing or organizing tasks, forgetfulness, ...

Families are elated by news of the first treatment for Huntington's disease - but when and how will the NHS fund it?

An experimental gene therapy slowed Huntington’s by up to 75 percent in a small clinical trial. While not a cure, it may give patients longer lives.

UCL and uniQure report the first treatment to slow Huntington’s disease with gene therapy AMT-130. High-dose patients had 75% less progression over three years compared with standard care. uniQure ...

Scientists have slowed the progression of Huntington’s disease for the first time with a “groundbreaking” new treatment. Experts from University College London (UCL) said the finding could “change ...

TAMPA, Fla. (WFLA) — For the first time, scientists have successfully treated someone suffering from Huntington’s disease, a fatal genetic illness with no cure. The Mayo Clinic reports that the ...

Why do some brain cells die first in HD? New study shows changes in gene activity begin at birth in mice, especially in striatum & cortex—mapped with spatial & single-cell tools. A new study in mouse ...